3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Polycystic Ovary Syndrome
21
Glioblastoma
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Leukoplakia, Oral
3
Insulin Resistance
3
Ovarian Neoplasms
2
Metabolic Syndrome
2
Metabolic Diseases
2
Medulloblastoma
2
Infertility
2
Erythroplasia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Adenocarcinoma Of Esophagus
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Diseases
1
TP53 Y220C Mutation
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Pleural Effusion, Malignant
1
Interventions
Alpelisib
2
exemestane
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Metformin
1
Letrozole
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Metformin
×
1 year
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled